15 Jul WisBusiness: Archeus Technologies is gearing up to apply for FDA approval
— A Madison-based startup called Archeus Technologies is gearing up to apply for FDA approval to begin human trials on a new targeting agent used in cancer therapy.
This cancer-targeting agent is being used by researchers at UW-Madison and the University of Pittsburgh School of Medicine, as part of a new cancer treatment that combines immunotherapy and radiation-based therapy.
Researchers found the simultaneous use of the two treatments reduced late-stage cancer in mice.
Radiation given via pills was administered in small doses to avoid damaging the “tumor-infiltrating immune cells” needed to fight the tumors, a University of Pittsburgh researcher said. The immunotherapy supplements are meant to boost the patient’s immune response, researchers said in a release.
Read full study results here: http://news.wisc.edu/combining-low-dose-radiotherapy-with-immunotherapy-eradicates-metastatic-cancer-in-mice/